Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 3:1-17.
doi: 10.1007/s12257-022-0268-5. Online ahead of print.

Cell-free Biosynthesis of Peptidomimetics

Kanghun Lee #  1 , Jessica A Willi #  2 , Namjin Cho  3 , Inseon Kim  1 , Michael C Jewett  2   4 , Joongoo Lee  1   3
Affiliations
Review

Cell-free Biosynthesis of Peptidomimetics

Kanghun Lee et al. Biotechnol Bioprocess Eng. .

Abstract

A wide variety of peptidomimetics (peptide analogs) possessing innovative biological functions have been brought forth as therapeutic candidates through cell-free protein synthesis (CFPS) systems. A key feature of these peptidomimetic drugs is the use of non-canonical amino acid building blocks with diverse biochemical properties that expand functional diversity. Here, we summarize recent technologies leveraging CFPS platforms to expand the reach of peptidomimetics drugs. We also offer perspectives on engineering the translational machinery that may open new opportunities for expanding genetically encoded chemistry to transform drug discovery practice beyond traditional boundaries.

Keywords: cell-free protein synthesis systems; non-canonical amino acids; peptidomimetics; translational machinery.

PubMed Disclaimer

Conflict of interest statement

M.C.J. is a cofounder of SwiftScale Biologics, Stemloop, Inc., Design Pharmaceuticals, and Pearl Bio. The interests of M.C.J. are reviewed and managed by Northwestern University in accordance with their competing interest policies. All other authors declare no competing interests. Neither ethical approval nor informed consent was required for this study.

References

    1. Otvos L., Jr. Peptide-based drug design: here and now. Methods Mol. Biol. 2008;494:1–8. doi: 10.1007/978-1-59745-419-3_1. - DOI - PubMed
    1. Ratnaparkhi M P, Chaudhari S P, Pandya V A. Peptides and proteins in pharmaceuticals. Int. J. Curr. Pharm. Res. 2011;3:1–9.
    1. Baker N M, Der C J. Cancer: drug for an ‘undruggable’ protein. Nature. 2013;497:577–578. doi: 10.1038/nature12248. - DOI - PMC - PubMed
    1. Nero T L, Morton C J, Holien J K, Wielens J, Parker M W. Oncogenic protein interfaces: small molecules, big challenges. Nat. Rev. Cancer. 2014;14:248–262. doi: 10.1038/nrc3690. - DOI - PubMed
    1. Brown E D, Wright G D. Antibacterial drug discovery in the resistance era. Nature. 2016;529:336–343. doi: 10.1038/nature17042. - DOI - PubMed

LinkOut - more resources